全文获取类型
收费全文 | 783篇 |
免费 | 48篇 |
国内免费 | 1篇 |
专业分类
林业 | 26篇 |
农学 | 13篇 |
基础科学 | 2篇 |
57篇 | |
综合类 | 123篇 |
农作物 | 30篇 |
水产渔业 | 20篇 |
畜牧兽医 | 521篇 |
园艺 | 12篇 |
植物保护 | 28篇 |
出版年
2021年 | 10篇 |
2020年 | 9篇 |
2019年 | 12篇 |
2018年 | 12篇 |
2017年 | 14篇 |
2016年 | 18篇 |
2015年 | 10篇 |
2013年 | 32篇 |
2012年 | 13篇 |
2011年 | 32篇 |
2010年 | 22篇 |
2009年 | 25篇 |
2008年 | 25篇 |
2007年 | 23篇 |
2006年 | 30篇 |
2005年 | 22篇 |
2004年 | 21篇 |
2003年 | 16篇 |
2002年 | 25篇 |
2001年 | 27篇 |
2000年 | 26篇 |
1999年 | 19篇 |
1998年 | 13篇 |
1997年 | 11篇 |
1996年 | 8篇 |
1995年 | 11篇 |
1994年 | 13篇 |
1993年 | 12篇 |
1992年 | 24篇 |
1991年 | 15篇 |
1990年 | 9篇 |
1989年 | 21篇 |
1988年 | 11篇 |
1987年 | 8篇 |
1986年 | 8篇 |
1985年 | 14篇 |
1984年 | 15篇 |
1983年 | 9篇 |
1979年 | 15篇 |
1978年 | 6篇 |
1977年 | 7篇 |
1976年 | 10篇 |
1974年 | 15篇 |
1973年 | 6篇 |
1972年 | 10篇 |
1971年 | 11篇 |
1970年 | 10篇 |
1969年 | 8篇 |
1967年 | 7篇 |
1966年 | 6篇 |
排序方式: 共有832条查询结果,搜索用时 15 毫秒
101.
102.
103.
Association of Helicobacter with cholangiohepatitis in cats 总被引:1,自引:0,他引:1
Greiter-Wilke A Scanziani E Soldati S McDonough SP McDonough PL Center SA Rishniw M Simpson KW 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2006,20(4):822-827
Infection with Helicobacter spp. is increasingly linked with hepatobiliary inflammation and neoplasia in people and in a variety of animals. We sought to determine if Helicobacter species infection is associated with cholangiohepatitis in cats. Deoxyribonucleic acid was extracted from tissue blocks from cats with cholangiohepatitis (32), noninflammatory liver disease (13), and cats with normal liver histology (4). Deoxyribonucleic acid was polymerase chain reaction-amplified with 2 sets of Helicobacter genus-specific primers, gel purified, and sequenced. Polymerase chain reaction-positive hepatic tissue was further examined with Steiner's stain, immunocytochemistry for Helicobacter species, and eubacterial fluorescent in situ hybridization. Gastric tissues of cats with known Helicobacter infection status served as controls for deoxyribonucleic acid extraction and sequence comparison. Helicobacter species were detected in 2/32 cats with cholangiohepatitis, and 1/17 controls. Sequences had 100% identity with Helicobacter species liver, Helicobacter pylori, and Helicobacter fenelliae/cinaedii in a cat with suppurative cholangitis, Helicobacter species liver, Helicobacter pylori, and Helicobacter nemistrineae in a cat with mild lymphocytic portal hepatitis, and Helicobacter bilis in a cat with portosystemic vascular anomaly. In contrast, sequences from gastric biopsies showed highest homology (99-100%) to "Helicobacter heilmannii," Helicobacter bizzozeronii, Helicobacter felis, and Helicobacter salomonis. Fluorescent in situ hybridization revealed a semicurved bacterium, with Helicobacter-like morphology, in an intrahepatic bile duct of the cat with suppurative cholangitis. This study has identified Helicobacter deoxyribonucleic acid in 2/32 cats with cholangiohepatitis and 1/13 cats with noninflammatory liver disease. Deoxyribonucleic acid sequences of hepatic Helicobacter species were distinct from those found in the stomach and are broadly consistent with those identified in cat intestine and bile, and hepatobiliary disease in people and rodents. 相似文献
104.
Rigas JD Smith TJ Gorman ME Valentine BA Simpson JM Seguin B 《Veterinary clinical pathology / American Society for Veterinary Clinical Pathology》2012,41(1):141-146
An 8-year-old male neutered Pomeranian dog was presented to the Veterinary Teaching Hospital at Oregon State University for surgical treatment of hydronephrosis of the left kidney and a left cranial abdominal mass. A primary ureteral mass was found during exploratory surgery, and the mass was resected and ureteral anastomosis was performed. Cytologic evaluation of the mass revealed 3 distinct cell populations, including a large number of multinucleated giant cells, a moderate number of thin spindle-shaped cells, and cohesive clusters of transitional epithelial cells. The cytologic diagnosis was giant cell sarcoma. The diagnosis was confirmed by histologic examination, and immunohistochemical staining was performed. The spindle-shaped cells and multinucleated giant cells were both immunoreactive for vimentin and spindle-shaped cells for S-100. Tumor cells did not express wide-spectrum cytokeratin, broad-spectrum muscle actin, smooth muscle actin, sarcomeric actin, desmin, BLA36, Mac 387, synaptophysin, neuron-specific enolase, glial fibrillary acid protein, or von Willebrand factor. These findings are most consistent with an anaplastic sarcoma with giant cells. This is the first case report of a primary ureteral giant cell sarcoma in a dog. 相似文献
105.
Sharkey LC Simpson RM Wellman ML Craig LE Birkebak TA Kock ND Miller MA Harris RK Munson L;ACVP Training Program Development Task Force 《Veterinary pathology》2012,49(4):581-585
Veterinary pathologists traditionally have been actively engaged in research as principal investigators and as collaborators. Pathologists frequently obtain advanced training in research; however, it appears that in the last 10 years there has been a reversal of a previous trend toward increasing numbers of pathologists obtaining PhD degrees. This has arisen despite an established shortage of veterinarians engaged in research. This article evaluates the benefits of research training for individual pathologists, including a wide spectrum of professional opportunities and additional skill development beyond that usually provided by diagnostic pathology training alone. Various training models are discussed, including combined and sequential diagnostic residency and research degree training as well as the nondegree research fellowship programs more commonly pursued in human medicine. Best-practice recommendations for program infrastructure, mentorship, time management, and a team approach to research and research training are advocated to facilitate the development of successful programs and to encourage a continued emphasis on integrated training for pathologists as both clinical diagnosticians and experimentalists. This article is intended to help prospective and active pathology trainees, their mentors, and educational administrators optimize opportunities to ensure the future vitality of veterinary pathologists, and their contributions, in basic and applied research. 相似文献
106.
Vail DM Husbands BD Kamerling SG Simpson H Kurzman ID McDonnell A 《Journal of veterinary internal medicine / American College of Veterinary Internal Medicine》2012,26(3):608-613
Background
Idarubicin, a PO bioavailable anthracycline antibiotic‐class chemotherapeutic, could have substantial convenience advantages over currently available similar class agents in use that require IV delivery.Objectives
The primary objective of this study was to determine the maximally tolerated dose (MTD), dose‐limiting toxicities (DLTs), and basic pharmacokinetic parameters of oral idarubicin exposure in dogs with lymphoma after a single oral dose. A secondary objective was to document preliminary antitumor efficacy in an expanded treatment cohort using the established MTD.Animals
Client‐owned dogs with measurable lymphoma.Methods
Dogs (n = 31) were enrolled in a prospective open label phase I study of oral idarubicin. By means of a 3 + 3 cohort design, dose escalations were made with 3 dogs per dose level, and the MTD was established based on the number of patients experiencing a DLT. Plasma concentrations of idarubicin and idarubicinol were determined by postdose sampling. Assessment of antitumor efficacy focused on evaluation of accessible, measurable lymph nodes and skin lesions by modified RECIST guidelines.Results
The MTD in dogs > 15 kg body weight was 22 mg/m2. Adverse hematologic events (neutropenia and thrombocytopenia) were the predominant DLT and generally correlated with higher plasma concentrations of idarubicin and idarubicinol.Conclusions and Clinical Importance
PO administered idarubicin was generally well‐tolerated and had preliminary antitumor activity in dogs with lymphoma. Furthermore, the potential clinical advantage of a safe and efficacious oral anthracycline alternative supports further investigations of this agent in repeated‐dose, randomized clinical trials. 相似文献107.
108.
109.
110.